IVF Reads / Genetics and Infertility: Which Tests Couples Actually Need
Genetics and Infertility: Which Tests Couples Actually Need

Genetic testing is not a routine first step for couples with infertility; it is indicated by specific findings. ESHRE's recurrent pregnancy loss guideline (2018, unchanged in its 2022 update) says parental karyotyping is not routinely recommended and could be done after individual assessment of risk. ESHRE's 2024 premature ovarian insufficiency guideline recommends chromosomal analysis and FMR1 premutation testing for all women with non-iatrogenic POI. Carrier screening, which ACMG (2021) recommends offering to everyone planning a pregnancy, assesses risk to a future child rather than explaining infertility.
- ESHRE RPL guideline (2018; genetic recommendations unchanged in 2022): parental karyotyping is not routinely recommended in couples with recurrent pregnancy loss; it could be carried out after individual assessment of risk.
- Franssen 2005 (BMJ, 279 carrier and 428 non-carrier couples after two or more miscarriages): the probability of carrying a chromosome abnormality ranged from 0.5% to 10.2%, depending on maternal age, three or more miscarriages, and miscarriages in siblings or parents.
- Franssen 2006 (BMJ, mean follow-up 5.8 years): at least one healthy child in 83% of carrier couples and 84% of non-carrier couples, despite further miscarriage in 49% (120 of 247) of carrier couples against 30% (122 of 409).
- ESHRE RPL guideline: the limited evidence for preimplantation genetic testing in couples with recurrent pregnancy loss shows no clear benefit.
- ESHRE POI guideline (2024): chromosomal analysis and FMR1 premutation testing are recommended for all women with non-iatrogenic premature ovarian insufficiency, and female relatives should be counselled that they are at increased risk.
- ACMG 2021: all patients planning a pregnancy should be offered Tier 3 carrier screening; broader Tier 4 screening should be considered when partners are second cousins or closer.
- ICMR-coordinated multicentre study (Mohanty 2013, 56,780 people in six Indian cities): beta-thalassaemia trait prevalence 2.78% overall, 1.48% to 3.64% by state, and 0 to 9.3% across 59 ethnic groups.
- ART (Regulation) Act 2021 s.25(1): pre-implantation genetic testing shall be used to screen the human embryo for known, pre-existing, heritable or genetic diseases only.
Do we need genetic testing because we are struggling to conceive?
Usually not as a first step. Genetic tests answer specific questions, and the guidelines tie each one to a specific trigger rather than to infertility in general. Without one of those triggers, the more useful next step is often ordinary testing, timing, or a simpler treatment.
The findings that do make a genetic test worth discussing:
- Two or more pregnancy losses — a chromosome test (karyotype) for both partners may be offered, but only after an individual risk assessment.
- Menopause or failing ovaries before 40 (premature ovarian insufficiency) — a chromosome test and a Fragile X premutation test are recommended.
- No sperm, or very few, on a semen analysis — a chromosome test and a Y-chromosome test for the man.
- A known genetic condition in either family, or partners who are related by blood — carrier screening, ideally before pregnancy.
Keep two kinds of test apart. Some tests look for a reason you are not conceiving or keep miscarrying. Carrier screening is different: it looks for conditions you could pass to a child, and most carriers have no fertility problem at all.
Should both partners have a karyotype after repeated miscarriage?
Not automatically. ESHRE's recurrent pregnancy loss guideline defines recurrent loss as two or more pregnancy losses and says parental karyotyping "is not routinely recommended" — it "could be carried out after individual assessment of risk". Its 2022 update reviewed the genetic recommendations and left them unchanged. Our page on recurrent pregnancy loss in couples covers the non-genetic investigations.
The risk assessment ESHRE refers to comes largely from a Dutch case-control study of 279 carrier couples and 428 non-carrier couples referred after two or more miscarriages. The chance that a couple carried a chromosome abnormality ranged from 0.5% to 10.2%, and four things moved it: the woman's age at the second miscarriage, three or more miscarriages rather than two, two or more miscarriages in a brother or sister of either partner, and two or more in either partner's parents.
Family history therefore matters, and it is worth asking your parents and siblings before the appointment. ESHRE also says testing the pregnancy tissue is not routinely recommended but may be done to explain a loss, using array-CGH where it is done.
If one of us carries a rearrangement, do we need IVF?
Not necessarily, and this is where a result is most often oversold. In the same Dutch cohort, couples in which one partner carried a structural chromosome abnormality miscarried more often, yet were as likely to have a healthy child as couples with normal results. An unbalanced chromosome abnormality was found at prenatal diagnosis in 2 of 550 pregnancies in carrier couples, and 2 of 550 ended in a child born with one: 0.4% each.
ESHRE's position is that every couple with an abnormal parental or pregnancy karyotype should receive genetic counselling and be told the treatment options, with their advantages and disadvantages. On IVF with embryo testing (PGT-SR) for this group, it says "the limited evidence for preimplantation genetic testing in couples with RPL shows no clear benefit". Trying again naturally, with prenatal testing available, is a legitimate choice and not a lesser one.
Embryo testing for a known rearrangement or a known single-gene condition is a different question from screening every embryo for chromosome count (PGT-A). Our page on what NICE, ASRM and ESHRE say about PGT-A covers that second test.
Who should be offered carrier screening, and what does it find?
Carrier screening checks whether each partner carries one copy of a gene change for a recessive condition. A carrier is usually healthy. The concern arises when both partners carry the same condition, because a child can then inherit it from both.
The American College of Medical Genetics and Genomics (ACMG, 2021) recommends that everyone who is pregnant or planning a pregnancy be offered screening for a defined list of 97 recessive genes and 16 X-linked genes; male partners may be offered screening at the same time. It prefers screening before pregnancy, because that leaves the full range of choices open. ACMG built that list from carrier frequencies in US populations and says plainly that it "may not adequately address" conditions more common in some populations, so family history should guide additional genes.
For Indian couples, beta-thalassaemia is the obvious example. A multicentre study coordinated with ICMR screened 56,780 college students and pregnant women in six cities, one of them in Karnataka. The prevalence of beta-thalassaemia trait was 2.78% overall, with state prevalence between 1.48% and 3.64%, and prevalence from 0 to 9.3% across 59 caste and ethnic groups. Two carriers of the same condition can have an affected child, and neither may know they are a carrier until they are tested.
We are related to each other. What does that change?
Marriage within the family is common in parts of India, especially the south, and nothing on this page is a judgement of it. An analysis of National Family Health Survey data (Kalam 2021, NFHS-1 and NFHS-4) found that, after adjusting for religion, wealth and other factors, women in the southern region had a relative risk ratio of 9.55 for first-cousin marriage and 38.16 for uncle-niece marriage compared with women in the northern region. Overall prevalence fell between the two surveys.
What it changes is the child's risk, not, on the evidence cited here, your ability to conceive. ACMG notes that related couples are more likely to carry the same recessive conditions, and recommends considering a broader carrier screening panel when partners are second cousins or closer. Tell the doctor at the first appointment. It is clinically useful information.
Early menopause runs in the family. Should that be tested?
If a woman has already been diagnosed with premature ovarian insufficiency, yes. The 2024 ESHRE guideline, developed with ASRM, recommends a chromosome test and an FMR1 (Fragile X) premutation test for every woman with POI that was not caused by surgery or treatment. Both are strong recommendations. Standard gene panels do not reliably detect the FMR1 premutation, so it has to be ordered as its own test. Our page on POI and pregnancy chances covers what the diagnosis means for treatment.
For her sisters and daughters, ESHRE says they should be told they are at increased risk, that "there are no established methods for predicting or preventing POI", and that some may wish to consider family planning and fertility preservation. Where a gene change such as the FMR1 premutation is found, relatives should be offered counselling and testing. If you are weighing egg freezing for this reason, note ESHRE's caution that for most women already diagnosed, the egg supply is too depleted for it.
What about the man's genetics?
When a semen analysis finds no sperm or very few, a chromosome test and a Y-chromosome microdeletion test are part of the standard work-up. Y microdeletions are the second most common identified genetic cause of male infertility after Klinefelter syndrome, and testing for them is routine in men with azoospermia or severe oligozoospermia. That, Klinefelter syndrome and the cystic fibrosis gene are covered in our page on genetic causes of male infertility, and our azoospermia guide explains why the obstructive and non-obstructive types lead to different decisions.
Been told to have a genetic test?
IVY can set out what the guideline says about that test for your situation, and what the result could and could not change.
What can a genetic result change, and what can it not?
A result can change four things: the explanation you are given, which relatives should be offered testing, whether testing embryos or a pregnancy is worth discussing, and whether donor eggs or sperm become a real option. ESHRE's POI guideline asks that the implications of a genetic test are discussed before it is done, not after.
It cannot change the gene or the chromosome, and no treatment reverses either. A normal carrier screen lowers the chance of an affected child without removing it: ACMG notes that screening covers only a minority of genetic conditions and cannot detect a new change arising in the child. A finding is biology handed down over generations, not something either of you did.
If a result points towards donor gametes, our page on when donor sperm or eggs make sense covers that decision. Under the Assisted Reproductive Technology (Regulation) Act 2021, section 25(1), embryo testing may be used "to screen the human embryo for known, pre-existing, heritable or genetic diseases only".
What the evidence does not establish
- That couples with no pregnancy losses, a normal semen analysis and no family history benefit from routine genetic testing. None of the guidelines cited here recommends it.
- That IVF with embryo testing improves the chance of a baby for couples with recurrent loss and a parental rearrangement. ESHRE finds no clear benefit.
- That being related to your partner lowers fertility. The sources here address the child's risk, not conception.
- That a family history of PCOS or endometriosis can be turned into a genetic diagnosis. Both run in families, but none of the guidelines cited here recommends a gene test for either.
- That genetic tests can tailor fertility drugs to your body. The page this replaces claimed so; we found no guideline that supports it.
- That a normal carrier screen means no risk. ACMG says it reduces the chance without eliminating it.
If none of the triggers on this page apply, unexplained infertility is the more likely frame, and genetic testing is unlikely to be where the answer is.
Keep reading
10 Sources
- ESHRE Guideline Group on RPL; Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S, et al. ESHRE guideline: recurrent pregnancy loss. Hum Reprod Open 2018;2018(2):hoy004. PMID 31486805. RPL defined as loss of two or more pregnancies; "Parental karyotyping is not routinely recommended in couples with RPL. It could be carried out after individual assessment of risk" (conditional); "The limited evidence for preimplantation genetic testing in couples with RPL shows no clear benefit of treatment." Human Reproduction Open (European Society of Human Reproduction and Embryology)
- ESHRE Guideline Group on RPL; Bender Atik R, et al. ESHRE guideline: recurrent pregnancy loss: an update in 2022. Hum Reprod Open 2023;2023(1):hoad002. PMID 36873081. Evidence on screening for genetic factors was reassessed and "did not require any amendments" to the 2018 recommendations. Human Reproduction Open (European Society of Human Reproduction and Embryology)
- ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI; Panay N, Anderson RA, Bennie A, Cedars M, Davies M, et al. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open 2024;2024(4):hoae065. PMID 39660328. Chromosomal analysis and FMR1 premutation testing recommended for all women with non-iatrogenic POI (strong); female relatives to be counselled on increased risk; sister oocyte donation carries shared genetic risk. Human Reproduction Open (European Society of Human Reproduction and Embryology)
- Franssen MT, Korevaar JC, van der Veen F, Leschot NJ, Bossuyt PM, Goddijn M. Reproductive outcome after chromosome analysis in couples with two or more miscarriages: index-control study. BMJ 2006;332(7544):759-63. PMID 16495333. At least one healthy child: 83% of carrier vs 84% of non-carrier couples; further miscarriage 120/247 (49%) vs 122/409 (30%); unbalanced karyotype 0.4% at prenatal diagnosis and 0.4% at birth among 550 carrier pregnancies. BMJ
- Franssen MT, Korevaar JC, Leschot NJ, Bossuyt PM, Knegt AC, Gerssen-Schoorl KB, et al. Selective chromosome analysis in couples with two or more miscarriages: case-control study. BMJ 2005;331(7509):137-41. PMID 15985440. Probability of carrier status 0.5% to 10.2%, modified by maternal age at second miscarriage, three or more miscarriages, and miscarriages in siblings or parents of either partner. BMJ
- Gregg AR, Aarabi M, Klugman S, Leach NT, Bashford MT, Goldwaser T, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021;23(10):1793-1806. PMID 34285390 (erratum PMID 34453133). Tier 3 screening (97 autosomal recessive, 16 X-linked genes) offered to all planning a pregnancy; Tier 4 considered for consanguinity (second cousins or closer). Genetics in Medicine (American College of Medical Genetics and Genomics)
- Mohanty D, Colah RB, Gorakshakar AC, Patel RZ, Master DC, Mahanta J, et al. Prevalence of beta-thalassemia and other haemoglobinopathies in six cities in India: a multicentre study. J Community Genet 2013;4(1):33-42. PMID 23086467. 56,780 screened; beta-thalassaemia trait 2.78% overall, 1.48-3.64% by state, 0-9.3% across 59 ethnic groups. Journal of Community Genetics
- Kalam MA, Sharma SK, Ghosh S, Roy S. Change in the prevalence and determinants of consanguineous marriages in India between National Family and Health Surveys of 1992-1993 and 2015-2016. Hum Biol 2021;92(2):93-113. PMID 33639640. Southern vs northern region relative risk ratios: first-cousin 9.55, uncle-niece 38.16; overall prevalence declined. Human Biology
- Witherspoon L, Dergham A, Flannigan R. Y-microdeletions: a review of the genetic basis for this common cause of male infertility. Transl Androl Urol 2021;10(3):1383-1390. PMID 33850774. Y-microdeletions are the second most commonly identified genetic cause of male infertility after Klinefelter syndrome; AZF testing is part of the routine work-up in azoospermia and severe oligozoospermia. Translational Andrology and Urology
- The Assisted Reproductive Technology (Regulation) Act, 2021 (No. 42 of 2021), section 25(1): "The Pre-implantation Genetic testing shall be used to screen the human embryo for known, pre-existing, heritable or genetic diseases only." Gazette of India, Ministry of Law and Justice
Frequently asked questions
Questions this page has not already answered.
Does Indian law allow embryo testing for a condition we already carry?
Yes, within limits. The Assisted Reproductive Technology (Regulation) Act 2021, section 25(1), says pre-implantation genetic testing shall be used to screen the human embryo for known, pre-existing, heritable or genetic diseases only. The Act defines pre-implantation genetic diagnosis as testing done when one or both genetic parents has a known genetic abnormality, to find out whether the embryo also carries it. Section 25(3) lets the National Board set further conditions.
Can my sister donate eggs if early menopause runs in our family?
She can, but ESHRE's 2024 POI guideline says a woman with non-iatrogenic POI considering eggs donated by her sister should be told this includes shared genetic risk and carries a higher risk of the stimulation cycle being cancelled. The guideline also recommends investigating the cause of POI before egg donation.
One of us is a thalassaemia carrier. Does the other need testing?
Yes. Risk to a child arises only if both partners carry a change in the same gene, so the partner's result is what decides it. ACMG's 2021 practice resource says that when one partner is a carrier, the other should have the full gene sequenced, not just a limited panel of common variants. If the partner cannot be tested, ACMG recommends offering a diagnostic procedure in pregnancy instead.
Is Turner syndrome a reason to avoid pregnancy with donor eggs?
Not automatically, but ESHRE's 2024 POI guideline classes pregnancy in women with Turner syndrome as high risk. It recommends cardiac screening and counselling by a maternal-fetal medicine specialist and a cardiologist with Turner syndrome experience before planning a pregnancy, especially if egg or embryo donation is being considered.


